Home  |  Contact

UniProtKB/Swiss-Prot Q13510: Variant p.Val97Glu

Acid ceramidase
Gene: ASAH1
Variant information

Variant position:  97
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  Disease [Disclaimer]
The variants are classified into three categories: Disease, Polymorphism and Unclassified.
  • Disease: Variants implicated in disease according to literature reports.
  • Polymorphism: Variants not reported to be implicated in disease.
  • Unclassified: Variants with uncertain implication in disease according to literature reports. Evidence against or in favor of a pathogenic role is limited and/or conflicting.

Residue change:  From Valine (V) to Glutamate (E) at position 97 (V97E, p.Val97Glu).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from medium size and hydrophobic (V) to medium size and acidic (E)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  -2
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  In FRBRL; decreased ceramide catabolic process.
Any additional useful information about the variant.



Sequence information

Variant position:  97
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  395
The length of the canonical sequence.

Location on the sequence:   VNSLKNMINTFVPSGKIMQV  V DEKLPGLLGNFPGPFEEEMK
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         VNSLKNMINTFVPSGKIMQVVDEKLPGLLGNFPGPFEEEMK

Chimpanzee                    VNSLKNMINTFVPSGKIVQVVDEKLPGLLGNFPGPFEEEMK

Mouse                         VNSITSLVNTFVPSGKLMKMVDQKLPGMIGSLPDPFGEEMR

Rat                           VNSISNLVNAFVPSGKIMQMVDEKLPGLIGSIPGPFGEEMR

Bovine                        VNSMKNIVNAFVPSGKIIHLVDQKLPGLLGNFPGPFEEEMK

Caenorhabditis elegans        IGVLINLITPWFPNA--IDFVDDVFGDLAPKLAQPYRDEIF

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 22 – 142 Acid ceramidase subunit alpha
Disulfide bond 31 – 340 Interchain (between alpha and beta subunits)
Alternative sequence 73 – 101 Missing. In isoform 3.
Mutagenesis 80 – 80 L -> Q. No effect on autocatalytic processing, but loss of ceramidase activity, when associated with 165-Q--Q-167.
Helix 90 – 105


Literature citations

Mutation analysis of the acid ceramidase gene in Japanese patients with Farber disease.
Muramatsu T.; Sakai N.; Yanagihara L.; Yamada M.; Nishigaki T.; Kokubu C.; Tsukamoto H.; Ito M.; Inui K.;
J. Inherit. Metab. Dis. 25:585-592(2002)
Cited for: VARIANTS FRBRL VAL-96 DEL; GLU-97 AND ARG-235; CHARACTERIZATION OF VARIANTS FRBRL VAL-96 DEL; GLU-97 AND ARG-235; VARIANT ILE-369; CATALYTIC ACTIVITY;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.